Advanced search
Publication Cover
Vascular Health and Risk Management Volume 8, 2012 - Issue
Submit an article Journal homepage
58
Views
18
CrossRef citations to date
0
Altmetric
Original Research

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

Julia A Gaebler1 Amylin Pharmaceuticals, Inc, San Diego CACorrespondence[email protected]
,
Gerardo Soto-Campos2 Archimedes Inc, San Francisco CA
,
Peter Alperin2 Archimedes Inc, San Francisco CA
,
Marc Cohen2 Archimedes Inc, San Francisco CA
,
Amy Blickensderfer1 Amylin Pharmaceuticals, Inc, San Diego CA
,
Matthew Wintle1 Amylin Pharmaceuticals, Inc, San Diego CA
,
David Maggs1 Amylin Pharmaceuticals, Inc, San Diego CA
,
Byron Hoogwerf3 Eli Lilly and Company, Indianapolis, IN, USA
,
Jenny Han1 Amylin Pharmaceuticals, Inc, San Diego CA
,
Richard Pencek1 Amylin Pharmaceuticals, Inc, San Diego CA
&
Barbara Peskin2 Archimedes Inc, San Francisco CA
 show all
Pages 255-264 | Published online: 23 Apr 2012

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Piaopiao Li, Rahul Patel, Jingchuan Guo, Scott M. Vouri, Lizheng Shi, Vivian Fonseca & Hui Shao. (2021) The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010–2018. Current Medical Research and Opinion 37:11, pages 1875-1880.
Read now
Wuquan Deng, Sheng Qiu, Gangyi Yang & Bing Chen. (2015) Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives. Therapeutics and Clinical Risk Management 11, pages 1153-1162.
Read now
Marisa B Schauerhamer, Holly Gurgle & Carrie McAdam-Marx. (2015) Once-weekly exenatide as a treatment for Type 2 diabetes. Expert Review of Cardiovascular Therapy 13:6, pages 611-626.
Read now
Sheila A Doggrell. (2013) Exenatide extended-release; clinical trials, patient preference, and economic considerations. Patient Preference and Adherence 7, pages 35-45.
Read now
Courtney Aavang Tibble, Tricia Santos Cavaiola & Robert R Henry. (2013) Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature. Expert Review of Endocrinology & Metabolism 8:3, pages 247-259.
Read now
Giuseppe Derosa & Pamela Maffioli. (2012) Optimizing glycemic control: clinical utility of exenatide prolonged release injection. Research and Reports in Endocrine Disorders 2, pages 41-51.
Read now

Articles from other publishers (12)

Chen-Yi Yang, Ying-Ren Chen, Huang-Tz Ou & Shihchen Kuo. (2021) Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovascular Diabetology 20:1.
Crossref
Bhavani Shankara Bagepally, Usa Chaikledkaew, Yogesh Krishnarao Gurav, Thunyarat Anothaisintawee, Sitaporn Youngkong, Nathorn Chaiyakunapruk, Mark McEvoy, John Attia & Ammarin Thakkinstian. (2020) Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Research & Care 8:1, pages e001020.
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Néboa Zozaya, Margarita Capel, Susana Simón & Alfonso Soto-González. (2019) A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031987657.
Crossref
K Gadkar, DC Kirouac, DE Mager, PH van der Graaf & S Ramanujan. (2016) A Six‐Stage Workflow for Robust Application of Systems Pharmacology. CPT: Pharmacometrics & Systems Pharmacology 5:5, pages 235-249.
Crossref
Yahiya Y. Syed & Paul L. McCormack. (2015) Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus. Drugs 75:10, pages 1141-1152.
Crossref
Saul Genuth. (2015) Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It’s Time to Move On!. Diabetes Care 38:1, pages 170-175.
Crossref
Namyi Gu, Sang-Heon Cho, JaeWoo Kim, Dongseong Shin, Eunyoung Seol, Heeyong Lee, Kyoung Soo Lim, Sang-Goo Shin, In-Jin Jang & Kyung-Sang Yu. (2014) Pharmacokinetic Properties and Effects of PT302 After Repeated Oral Glucose Loading Tests in a Dose-Escalating Study. Clinical Therapeutics 36:1, pages 101-114.
Crossref
José A. Pagán & Erin K. Carlson. (2013) Assessing Long-Term Health and Cost Outcomes of Patient-Centered Medical Homes Serving Adults With Poor Diabetes Control. Journal of Primary Care & Community Health 4:4, pages 281-285.
Crossref
Gina J. Ryan, Nader H. Moniri & Dawn D. Smiley. (2013) Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. American Journal of Health-System Pharmacy 70:13, pages 1123-1131.
Crossref
Patrick English. (2013) Insulin: standard therapy following oral hypoglycaemic failure in type 2 diabetes?. British Journal of Hospital Medicine 74:4, pages 192-197.
Crossref
Lesley J. Scott. (2012) Exenatide Extended-Release. Drugs 72:12, pages 1679-1707.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.